Jasper Therapeutics

JSPR

Redwood City, United States· Est. 2018

jaspertherapeutics.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

JSPR · Stock Price

USD 0.91-3.61 (-79.91%)

Market Cap: $26.2M

Historical price data

Overview

Jasper Therapeutics is on a mission to redefine conditioning for stem cell transplants and gene therapies by replacing toxic chemotherapy with targeted antibody-based regimens. Its core achievement is the development of briquilimab, a first-in-class anti-c-Kit antibody, which has demonstrated proof-of-concept in clinical trials for multiple indications. The company's strategy focuses on advancing briquilimab through key registrational studies in Severe Combined Immunodeficiency (SCID) and leveraging its platform to enable next-generation gene therapies, positioning itself at the intersection of transplant medicine and genetic medicine.

HematologyImmunologyGenetic DisordersOncology

Technology Platform

Targeted antibody-based platform for non-genotoxic conditioning, centered on the depletion of hematopoietic stem cells via the c-Kit (CD117) receptor to enable safer stem cell transplants and gene therapies.

Pipeline

7 drugs in pipeline

Drug	Indication	Stage
Briquilimab	Urticaria Chronic	Phase 2
Briquilimab	Chronic Spontaneous Urticaria	Phase 1/2
Briquilimab	Chronic Inducible Urticaria	Phase 1/2
Humanized anti-CD117 Monoclonal Antibody (JSP191)	SCID	Phase 1/2
JSP191	Lower-risk Myelodysplastic Syndrome	Phase 1

Opportunities

Briquilimab could establish a new standard of care in SCID and other non-malignant transplant settings, addressing a severe unmet need.

Its long-term, high-value opportunity lies in becoming an enabling platform for safer conditioning across the rapidly growing ex vivo gene therapy landscape.

Risk Factors

The company faces high clinical development risk, with its future dependent on briquilimab's success in ongoing trials.

Financial risk is acute, with a need to raise additional capital likely before achieving profitability, potentially causing shareholder dilution.

Market adoption risk exists in displacing entrenched, low-cost chemotherapy-based conditioning regimens.

Competitive Landscape

Jasper's primary competition is the entrenched standard of care: toxic chemotherapy and radiation. In targeted conditioning, it holds a first-mover advantage with briquilimab, following the discontinuation of Magenta Therapeutics' competing ADC program. Its main competitive edge is clinical proof-of-concept and a potentially superior safety profile as a naked antibody.